€11.25
0.59% today
L&S, Jul 02, 07:23 pm CET
ISIN
US29082K1051
Symbol
EMBC
Sector

Embecta Share price

$12.15
-0.67 5.23% 1M
-6.78 35.82% 6M
-6.78 35.82% YTD
-8.85 42.14% 1Y
-34.85 74.15% 3Y
-34.85 74.15% 5Y
-34.85 74.15% 10Y
NYSE, Closing price Mon, Jul 01 2024
-0.35 2.80%
ISIN
US29082K1051
Symbol
EMBC
Sector

Key metrics

Market capitalization $700.69m
Enterprise Value $2.05b
PER (TTM) P/E ratio 9.98
EV/FCF (TTM) EV/FCF 218.07
EV/Sales (TTM) EV/Sales 1.81
P/S ratio (TTM) P/S ratio 0.62
P/B ratio (TTM) P/B ratio negative
Dividend yield 4.94%
Last dividend (FY23) $0.60
Sales growth (TTM) Sales growth 1.25%
Turnover (TTM) Turnover $1.13b
EBIT (operating result TTM) EBIT $228.40m
Free cash flow (TTM) Free cash flow $9.40m
Cash position $306.50m
EPS (TTM) EPS $1.22
P/E ratio expected 7.79
P/S ratio expected 0.63
EV/Sales expected 1.84
Short interest 8.08%
Show more

Is Embecta a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.

Embecta Share analysis

Unlock Scores for Free

Analyst opinions

4 Analysts have issued a Embecta forecast:

2x Hold
50%
2x Sell
50%

Analyst opinions

4 Analysts have issued a Embecta forecast:

Hold
50%
Sell
50%

Financial data from Embecta

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
1,121 1,121
1% 1%
100%
- Direct costs 371 371
5% 5%
33%
750 750
3% 3%
67%
- Selling and administrative expenses 402 402
34% 34%
36%
- Research and development costs 85 85
31% 31%
8%
262 262
36% 36%
23%
- Depreciation and amortization 33 33
3% 3%
3%
EBIT (operating result) EBIT 230 230
39% 39%
20%
Net profit 70 70
69% 69%
6%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Embecta share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Embecta Share News

Neutral
GlobeNewsWire
8 days ago
PARSIPPANY, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, presented two abstracts at the American Diabetes Association's 84th Scientific Sessions that point to the potential for adults with type 2 diabetes (T2D) to better manage insulin delivery through a patch pump with a larger, 300-...
Neutral
PRNewsWire
12 days ago
WARSAW, Ind. , June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately.
Positive
InvestorPlace
about one month ago
The White House recently confirmed increased tariffs on various Chinese goods. Investors and traders are on the lookout for stocks to benefit from China tariffs as the change could significantly impact many industries, including the U.S. automotive industry, electric vehicles (EVs) and others.
More Embecta News

Company profile

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

Head office United States
CEO Devdatt Kurdikar
Employees 2,200
Founded 1924
Website www.embecta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today